Objective To investigate the efficacy of Wenxin Granules combined with Irbesartan in the treatment of heart failure (HF) accompanied by ventricular arrhythmia (VA)

and analyze its effects on cardiac function and serum levels of related cytokines. Methods A total of 83 patients with HF accompanied by VA at our hospital from October 2021 to October 2024 were prospectively selected as the study subjects. They were divided into a control group of 41 cases (treated with Irbesartan) and a study group of 42 cases (treated with Wenxin Granules combined with Irbesartan) using a random number table method. The therapeutic effects and adverse reactions of the two groups were observed

as well as the arrhythmia-related indicators [PR interval

heart rate-corrected QT interval (QTc)

standard deviation of the mean of normal R-R intervals per 5 minutes (SDANN)

root mean square of successive differences in normal R-R intervals (rMSSD)

and number of ventricular premature beats

]

cardiac function [left ventricular ejection fraction (LVEF)

cardiac output (CO)

left ventricular end-diastolic diameter (LVEDD)

and left ventricular end-systolic diameter (LVESD)

]

vascular endothelial function [endothelin-1 (ET-1)

vascular endothelial growth factor (VEGF)

nitric oxide (NO)

and brachial artery flow-mediated dilation (FMD)

]

and oxidative stress [propylene glycol (PG)

superoxide dismutase (SOD)

catalase (CTA)

matrix metalloproteinase-9 (MMP-9)

and lipid peroxides (LPO)

]

before and after treatment. Results The total effective rate of heart failure and arrhythmia in the study group was significantly higher than that in the control group (

P

<

0.05). After treatment

the PR interval

SDANN

rMSSD

LVEF

and CO in the study group were higher than those in the control group

while QTc

LVEDD

and LVESD were lower

and the number of ventricular premature beats was less than that in the control group (

P

<

0.05). After treatment

the serum

ET-1 level in the study group was lower than that in the control group

while the levels of NO

VEGF

and FMD were higher (

P

<

0.05). After treatment

the serum levels of PG

MMP-9

and LPO in the study group were lower than those in the control group

while the levels of SOD and CTA were higher (

P

<

0.05). There was no significant difference in the incidence of adverse reactions between the two groups (

P

>

0.05). Conclusions The combination of Wenxin Granules and Irbesartan in the treatment of patients with HF accompanied by VA can enhance clinical efficacy

alleviate arrhythmic symptoms

protect cardiac function

improve vascular endothelial function

inhibit oxidative stress response

and offer good safety.